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a  b  s  t  r  a  c  t
The  German  Human  Biomonitoring  Commission  (HBM  Commission)  derives  health-related  guidance
values  (Human  Biomonitoring  assessment  values,  HBM  values)  according  to  the  procedures  described
in  the  HBM  Commission’s  position  papers.  Since  the  last adaption  of the  methodology  in  2014,  the  HBM
Commission  has  established  a series  of  new  HBM  values,  mainly  on  the  basis  of internationally  agreed
TDI/RfD  values,  or  of  toxicologically  well-  founded  points  of departure  observed  in animal  studies.  The
derivation  of  these  new  HBM  values  for  HBCDD,  triclosan,  2-MBT,  PFOA and  PFOS  as  well as  for  the
metabolites  of  glycol  ethers,  of Hexamoll® DINCH® , DPHP,  DEHTP,  NMP,  NEP, and 4-MBC  is speciﬁed,
and  the  HBM  values  are  presented  together  with  already  established  HBM  values  for  other  substances.
Furthermore,  the HBM Commission  has  deﬁned  provisional  reference  values  for  2-methoxyacetic  acid
and for  several  parabens  in  the  urine  of  the German  population.  It has  also  updated  provisional  reference
values  for  PCB  in  the  blood  of the  German  population.  An  overview  of  all available  reference  values  is
given.
©  2016  Elsevier  GmbH.  All  rights  reserved.ontents
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. Introduction
Human biomonitoring (HBM) implies the determination of
uman’s internal exposure to chemicals and/or their metabolites
y analysing human biological matrices, predominantly human
ody ﬂuids (biomarkers of exposure). Additionally, HBM can be
sed to determine early effects of harmful substances (biomarkers
f effect). It plays a decisive role in the monitoring of pollutants
nd the evaluation of the exposure of a population, of popula-
ion sub-groups or individuals (Kommission HBM, 1996a). Based
n the Regulation (EC) No 1907/2006 concerning the Registration,
valuation, Authorisation, and Restriction of Chemicals (REACH),
ndustry is responsible for the risk assessment of substances and
heir safety throughout the substance’s life cycle. Monitoring to
nsure compliance with legislation on chemical safety is the task
o be accomplished by politics and the authorities providing scien-
iﬁc advice. Thus, HBM data can be used to assess if regulatory or
oluntary measures to reduce exposure are needed. It is also of use
o follow up the decrease of the population’s exposure to harmful
ubstances, i.e. those that have been banned or restricted for use.
With this paper a description is given of the science-based
pproaches for developing guidance values to interpret human
iomonitoring data. Furthermore an overview of the up-to date
uidance values is presented and the board responsible for the
etermination of the guidance values in Germany is introduced.
. The HBM Commission
The HBM Commission was established in 1992 and has the man-
ate to support the German Environment Agency by giving advice
oncerning HBM related issues.
The HBM Commission’s members are appointed every three
ears by the president of the German Environment Agency (at last
n 2016). They are scientists, experts from authorities at the fed-
ral and Bundesländer (Federal States) level, universities, public
ealth institutes and clinical institutes. In addition to regular mem-
ers, permanent guests are invited, representing the Permanent
orking Group of the Highest Health Authorities of the Federal
tates, the Federal Ministry for the Environment, Nature Conserva-Please cite this article in press as: Apel, P., et al., New HBM valu
values in force, and working principles of the German Human Bi
http://dx.doi.org/10.1016/j.ijheh.2016.09.007
ion, Building and Nuclear Safety, the Federal Ministry of Health,
he Robert Koch-Institute and the Federal Institute for Risk Assess-
ent. The main ﬁelds of activity of the HBM Commission include
or the appointment period 2013–2016: . . . .  . .  .  .  . . .  . .  .  . . . . . . .  . . . . .  . . .  . .  . . . . . .  . .  .  . . .  .  .  . .  . . .  .  .  .  . .  .  .  .  .  . . . .  . . . . .  .  . .  .  .  .  . .  00
• the derivation of health-related guidance values (HBM I and HBM
II values),
• the description of the background exposure of the population by
statistically derived reference values,
• the intensiﬁed examination of physiologically-based pharma-
cokinetic (PBPK) models,
• the advice for the planning and realisation of HBM studies, esp.
the German Environmental Survey 2014–2017, GerES V,
• the enhancement of international cooperation for reciprocal
transfer of knowledge in the ﬁeld of HBM and for a compara-
tive analysis of different evaluation methods (Kommission HBM,
2015a).
3. HBM values
Usually HBM values are derived for the general population
including all sub-groups and for an assumed lifelong exposure at
a corresponding level. Separate HBM values and recommendations
for action are derived for particularly vulnerable population groups
and/or certain phases of life (e.g. women of child-bearing age, chil-
dren and the elderly) if needed. The HBM I value represents the
concentration of a substance in human biological material at which
and below which, according to the current knowledge and assess-
ment by the HBM Commission, there is no risk of adverse health
effects, and, consequently, no need for action. The HBM II value
describes the concentration of a substance in human biological
material at which and above which adverse health effects are possi-
ble and, consequently, an acute need for the reduction of exposure
and the provision of biomedical advice is given.
For levels between the HBM I value and the HBM  II value adverse
health effects cannot be excluded any more with sufﬁcient certainty
and a follow-up examination should be performed to determine
whether there is a continued elevated exposure. If repeated mea-
surements conﬁrm the initial result a search for potential sources of
exposure should be undertaken. Exposure to such sources should
be minimized or eliminated when achievable with an acceptable
level of effort (Kommission HBM, 1996b).
In its new position paper, the HBM Commission describes
three methods for deriving HBM values (Kommission HBM, 2014a).
Firstly, HBM values can be derived on the basis of experiences withes for emerging substances, inventory of reference and HBM
omonitoring Commission. Int. J. Hyg. Environ. Health (2016),
humans. Epidemiological studies providing evidence of a relation-
ship between concentrations of a substance and/or its metabolites
in human body ﬂuids and the occurrence of adverse effects are
the best fundament for the value’s derivation. Secondly, HBM
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alues can be established on the basis of generally accepted tol-
rable intake values founded for their part on studies with animals,
r thirdly HBM values can be established on the basis of critical
ffects observed in animal experiments. To interpret the relation-
hip between the external dose and the levels measured in body
uids and vice versa basic toxicokinetic data are necessary. In spe-
ial cases the use of appropriate PBPK models (WHO  IPCS, 2010) is
elpful.
The urine volumes which have to be integrated in the calculation
f HBM values for the matrix urine are currently reviewed to make
ure that the 95th percentiles of the urine volumes of adults as well
s of children are actually used.
.1. Methods for deriving HBM values
.1.1. Derivation based on human data
The initial concept of HBM values in environmental medicine
ates back to 1996 (Kommission HBM, 1996b) and is based on
pidemiological data on human toxicity. The HBM values for lead
meanwhile suspended), cadmium, mercury, thallium, polychlo-
inated biphenyls (PCB) and pentachlorophenol were derived
ccording to this concept. By direct use of human data uncertain-
ies are avoided which are connected with the extrapolation of
oxicological data from animal studies to humans. Therefore, these
alues are the most reliable for the interpretation of the internal
uman exposure. However, sufﬁcient epidemiological data to
erive HBM values according to this concept are available only for
 limited number of substances. This is why other methods are
equired in addition to derive HBM values.
.1.2. Derivation based on a deﬁned tolerable intake
The extension of the HBM Commission’s tool box made in 2007
Kommission HBM, 2007a,b) introduced the approach to derive
BM I values on the basis of toxicologically substantiated tolerable
ntake values (e.g. ADI, TDI, PTWI or comparable values) which have
een determined by recognised bodies preferably at EU level, such
s EFSA. The HBM I value represents the TDI equivalent and is calcu-
ated by means of toxicokinetic extrapolation. Hence, a prerequisite
or the application of this method is the availability of reliable toxi-
okinetic information from humans. This concept was  used for the
rst time to derive the HBM I value for the sum of the DEHP metabo-
ites mono (2-ethyl-5-hydroxyhexyl) phthalate (5OH-MEHP) and
ono (2-ethyl-5-oxohexyl) phthalate (5oxo-MEHP) in urine. In
ccordance with this method, also biomonitoring equivalents (BE)
ay  be used to derive HBM I values. A BE is deﬁned as the concen-
ration of a chemical in blood or urine as referred to an acceptable
evel of exposure deﬁned as safe in the sense of the regulation, e.g.
 reference dose (RfD), or a tolerable daily intake (TDI) (Hays and
ylward, 2009; Angerer et al., 2011). A derivation of HBM II values
as not envisaged in the context of this derivation method.
.1.3. Derivation based on a critical effect seen in animal studies
The concept described above is limited due to the fact that there
re no ADI, TDI or comparable values for many (mainly new) chem-
cals, and those chemicals which have no relevance for the uptake
ia food. This is why the HBM Commission has decided to develop
 supplementing HBM value derivation scheme for substances for
hich sufﬁcient epidemiological data or TDI values are missing. At
he same time, the HBM Commission conﬁrmed the use of the two
ther derivation methods as far as possible.
The extended third method for deriving HBM values is based
n the identiﬁcation of a critical effect using data from studies withPlease cite this article in press as: Apel, P., et al., New HBM valu
values in force, and working principles of the German Human Bi
http://dx.doi.org/10.1016/j.ijheh.2016.09.007
xperimental animals. Based on different points of departure (POD),
BM I and HBM II values are derived by means of assessment factors
AF) and toxicokinetic extrapolation (Kommission HBM, 2014a).
part from establishing a TDI-like value, the same steps are applied PRESS
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as stipulated for the derivation of HBM I values based on the gen-
erally accepted tolerable intake (Kommission HBM, 2007a, 2007b).
a) Determination of the pivotal study
In principle, the derivation of HBM values using a POD is based
on acknowledged methods for toxicological evaluation as described
for example in the REACH procedure (ECHA, 2012). The aim is
to work with a procedure which is as transparent, uniform, and
comprehensible as possible. A ﬁrst step consists in an analysis of
the toxicodynamic and toxicokinetic data for the substance to be
assessed. The evaluation of the data leads to the identiﬁcation of
the most sensitive effect endpoints and the most sensitive species.
If the data are considered as sufﬁcient for an assessment, the next
step comprises the determination of the pivotal study (also referred
to as the critical or reference study). In order to minimize possi-
ble uncertainties in the derivation, also human studies should be
included (if available) in addition to the data from animal experi-
ments. Such studies in humans might not be suitable or adequate
in qualitative terms for deriving a HBM value based on the ﬁrst
method (see above), but they may  serve as an additional conﬁrma-
tion of the risk assessment based on animal testing data and the
extrapolation to humans. The pivotal study should preferably be
selected from studies using the route of exposure which is decisive
for humans. Possible routes of exposure include the oral and dermal
uptake as well as inhalation. If two routes of exposure are identi-
ﬁed as similarly decisive for the most sensitive adverse systemic
effect in humans, a comparative toxicokinetic evaluation (e.g. on
absorption, ﬁrst-pass effect etc.) is required for both routes.
b) Points of departure (POD) for the derivation of HBM values
Following the selection of the pivotal study, the HBM Commis-
sion determines the POD for further derivations. Based on the ﬁnal
Report by the Risk Commission (Risikokommission, 2003), possible
POD include:
• NOAEL,
• LOAEL, and
• Benchmark Dose
The POD may  consist in an external, administered dose or an
internal exposure concentration. In the majority of studies the
LOAEL, or NOAEL refer to an external dose taken up by the oral
route or inhalation.
In some cases, the benchmark method is used to establish tox-
icological parameters (Sand et al., 2008). After establishing the
benchmark response (BMR), the corresponding benchmark dose
(BMD) can be determined from the mathematical function. The
BMD  or also the unilateral lower 95% conﬁdence interval of the
BMD, referred to as BMDL (benchmark dose lower bound), can
be used as POD. Regarding the probability of occurrence of an
effect, the BMDL was  assigned as a basis for the HBM I value,
and the BMD  as a basis for the HBM II value, in accordance with
the deﬁnitions of HBM I and HBM II values. EFSA (2009) reported
about a reanalysis of a considerable number of studies by the
US National Toxicology Program (Bokkers and Slob, 2007) which
found that with continuous data the BMDL05 is, on average, close
to the NOAEL, if the same data set is used as a basis. Conse-
quently, EFSA (2009) decided for using the BMDL05 as a default for
the NOAEL of continuous data. Often, epidemiological studies use
signiﬁcantly larger data sets than studies based on animal exper-
iments do. Therefore, a BMDL01 can be derived on the basis of
such studies (EFSA, 2009, 2010). The application of the benchmark
method for the derivation of HBM values has been described in
detail by Schneider and Kaiser (2012) (research project 36301383es for emerging substances, inventory of reference and HBM
omonitoring Commission. Int. J. Hyg. Environ. Health (2016),
on behalf of the German Environment Agency). In any case, the
choice of the method and the POD will require a scientiﬁc sub-
stantiation. Without rigid provisions, but rather in the context of
an expert judgement, the HBM Commission decides on the points
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Table  1
Overview of all HBM values currently in force.
Analyte and sample material Population group HBM I value HBM  II value
Cadmium in urine [1998, 2011] Children and
adolescents
0.5 g/l 2 g/l
Adults 1 g/l 4 g/l
Mercury in urine [1999] Children and adults 7 g/l (5 g/g crea.) 25 g/l (20 g/g crea.)
Mercury in whole blood [1999] Children and adults 5 g/l 15 g/l
Thallium in urine [2011] General population 5 g/l /
Pentachlorophenol (PCP) in serum [1997] General population 40 g/l 70 g/l
Pentachlorophenol (PCP) in urine [1997] General population 25 g/l (20 g/g crea.) 40 g/l (30 g/g crea.)∑
DEHP metabolites 5-oxo- and 5-OH-MEHP in urine [2007] Children aged 6–13 500 g/l /
Women  of
child-bearing age
300 g/l
Men  aged 14 and older
as well as remaining
general population
750 g/l
Bisphenol A in urine [2012, updated 2015] Children
Adults
0.1 mg/l
0.2 mg/l
/
∑
of PCB (138 + 153 + 180) in serum × 2 [2012] Infants, small children
and women of
child-bearing age
3.5 g/l 7 g/l
Glycolether which are metabolized to 2- methoxyacetic acid (MAA), urine [2014] General population 0.4 mg MAA/g
creatinine
1.6 mg MAA/g
creatinine
Glycolether which are metabolized to 2- ethoxyacetic acid (EAA), urine [2016] Adults 5 mg EAA/l /∑
DINCH® metabolites OH-MINCH and cx-MINCH in urine [2014] Children
Adults
3 mg/l
4.5 mg/l
/
∑
DPHP metabolites OH-MPHP and oxo- MPHP in urine [2015] Children
Adults
1 mg/l
1.5 mg/l
/
DEHTP metabolite 5cx-MEPTP in urine (publication in preparation) Children
Adults
1.8 mg/l
2.8 mg/l
/
Hexabromocyclododecane (HBCD(D)) [2015] General population 0.3 g/g lipid (1.6 g/l
blood plasma)
/
∑
N-methyl-2-pyrrolidone metabolites 5-hydroxy-NMP and
2-hydroxy-N-methylsuccinimide in urine [2015]
Children
Adults
10 mg/l
15 mg/l
30 mg/l
50 mg/l∑
N-ethyl-2-pyrrolidone metabolites 5-hydroxy-NEP and
2-hydroxy-N-ethylsuccinimide in urine [2015]
Children
Adults
10 mg/l
15 mg/l
25 mg/l
40 mg/l
Triclosan in urine [2015] Children
Adults
2 mg/l
3 mg/l
/
2-mercaptobenzothiazole (2-MBT) in urine [2015] Children
Adults
4.5 mg/l
7 mg/l
/
∑
3-(4-methylbenzylidene) camphor metabolites 3-4CBHC and 3-4CBC in urine [2016] Children
Adults
0.3 mg/l
0.5 mg/l
/
PFOA  in blood plasma [2016] General population 2 g/l /
o
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tPFOS  in blood plasma [2016] 
f departure for further derivation on the basis of the data avail-
ble, the dose-effect curve, the toxicological mechanisms, and the
everity and type of effect. The POD that served as a basis for deriv-
ng DNELs (derived no effect levels) in the context of the REACH
rocedure may  be used for deriving HBM values if all eligible stud-
es have been published, and both the selection procedure and
he methods of derivation have been made public and transpar-
nt.
In cases where no studies are available on the main route of
xposure, studies on other routes may  also be used in combina-
ion with a route-to-route extrapolation. This requires a POD which
efers to an adverse systemic effect of the substance. A prerequisite
or a route-to-route extrapolation consists in the similarity of the
ritical effects and of the toxicokinetics for the routes of exposure
oncerned (Rennen et al., 2004; IGHRC, 2006).
c) Use of assessment factors (AF)
After the critical study and the POD for deriving the HBM I and
BM II values have been determined, the assessment factors have
o be selected.
The HBM Commission has agreed to use the assessment fac-Please cite this article in press as: Apel, P., et al., New HBM valu
values in force, and working principles of the German Human Bi
http://dx.doi.org/10.1016/j.ijheh.2016.09.007
ors determined by consensus in the ECHA Guidance Document R.8
ECHA, 2012). The choice and magnitude of assessment factors have
o be justiﬁed in individual cases.General population 5 g/l /
The assessment factors are intended to take account of the fol-
lowing differences and uncertainties: LOAEL vs. NOAEL, duration
adjustment (time scaling), study duration adjustment (minimum:
subchronic study), interspecies differences, intraspecies differ-
ences, and other uncertainties (type of effect, severity of effect,
quality of data available).
If the POD represents a NOAEL or LOAEL, also the severity of the
toxic effect at the next higher dose level and the spacing of doses
used have to be taken into account for a reasonable evaluation. This
can be done by applying an additional assessment factor.
d) Taking into account the data quality
Generally, the derivation of HBM values is based on data pub-
lished in peer-reviewed scientiﬁc journals. The description of the
study conditions and the range of reported parameters are impor-
tant criteria for evaluating the data quality. The HBM Commission
evaluates the quality of the initial or pivotal study by using the
Klimisch criteria (Klimisch et al., 1997).es for emerging substances, inventory of reference and HBM
omonitoring Commission. Int. J. Hyg. Environ. Health (2016),
4. New HBM values for emerging substances
An overview of all available HBM values is given in Table 1.
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.1. HBM values for glycol ethers
.1.1. HBM values for glycol ethers which are metabolized to
-methoxyacetic acid (MAA)
Glycol ethers which are metabolized to alkoxyacetic acids are
ubstances of very high concern because of their repro-, hemato-,
nd neurotoxic effects. The biological monitoring of MAA is gener-
lly accepted for the quantitative detection of exposure to ethylene
lycol monomethyl ether (EGME), ethylene glycol monomethyl
ther acetate (EGMEA), and ethylene glycol dimethyl ether
EGDME). For the exposure of the general population inhalation
nd dermal absorption are relevant. The HBM Commission used a
enchmark dose relating to teratogenic effects in rabbits (Hanley
t al., 1984a,1984b) as POD for the derivation of HBM values. On
his basis a HBM I value of 0.4 mg  MAA/g creatinine and a HBM
I value of 1.6 mg  MAA/g creatinine have been derived. Especially
or pregnant women exposures at and above the HBM II value give
easons for concern. Risk management can be done by air measure-
ents to determine and, if required, avoid the source of exposure.
he use of cleaning supplies and cosmetic products should also be
raced and reduced if applicable (Kommission HBM, 2014b).
.1.2. HBM I value for glycol ethers which are metabolized to
-ethoxyacetic acid (EAA)
Ethylene glycol ethyl ether (EGEE) and ethylene glycol ethyl
ther acetate (EGEEA) are, as other glycol ethers, excellent solvents
or water and many organic substances. They are used amongst oth-
rs for the production of paints, lacquers, and cleaning agents. The
eneral population might be exposed via inhalation and dermal
bsorption. It is assumed that the metabolite EAA is responsi-
le for the toxic effects of EGEE and EGEEA on hematopoiesis
nd reproduction (Welsch, 2005). The NOEL of 50 ppm for feto-
oxicity and fetal defects in rats and rabbits (Doe, 1984) has
een determined as POD. According to the PBTK extrapolation
f Gargas et al. (2000) maternal EAA blood concentrations that
qual those at the NOEL for rats are given, if pregnant women  are
xposed to 25 ppm of ethylene glycol ethyl ether (EGEE) for 8 h/day,
 days/week. This corresponds to an average weekly exposure of
.0 ppm (25 ppm × 8/24 × 5/7), or 22.1 mg  EGEE/m3. With an alveo-
ar ventilation rate of Qalv = 7.9 m3/day (for a 60 kg woman), a daily
ntake of 175 mg  EGEE, or 2.91 mg  EGEE/kg bw/day is equivalent to
he NOEL.
Taking into account the inter-individual variability, studied by
weeney et al. (2001), an assessment factor of 1.8 for toxicokinetics
as to be applied together with an AF of 3.2 for the toxicodynamic
ntraspecies variability and an AF of 2.5 for the toxicodynamic inter-
pecies variability (total AF of 14.4) to get a TDI-like value of 0.2 mg
GEE/kg bw/day.
With a molar-based fue of 0.42, a Fmol in mg  EAA/mg EGEE of 1.2
nd an urine volume of adults of 0.02 l/kg bw/day the HBM I value
or adults was calculated as follows: 0.2 × 0.42 × 1.2: 0.02 = 5 mg
AA/l urine. This HBM I value applies to the joint exposure to EGEE
nd EGEEA (Kommission HBM, 2016a).
Since the whole body was exposed to EGEE in the animal study,
nd rodent skin is nearly always more permeable to solvent vapour
han human skin, the dermal uptake of vapour is inherent in the rat
OEL value (Sweeney et al., 2001).
.2. HBM I values for the sum of Hexamoll
®
DINCH
®
metabolites
H-MINCH and cx-MINCH
Hexamoll
®
DINCH
®
(cyclohexane-1,2-dicarboxylic acid-Please cite this article in press as: Apel, P., et al., New HBM valu
values in force, and working principles of the German Human Bi
http://dx.doi.org/10.1016/j.ijheh.2016.09.007
iisononyl ester or diisononyl cyclohexane-1,2-dicarboxylate) is a
lasticiser used in plastic articles. It was developed as a substitute
or bis(2-ethylhexyl) phthalate (DEHP) which has been shown
n animal studies to be toxic for reproduction (Cat. 1B). DINCH PRESS
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has, according to the current state of knowledge, more favourable
toxicological properties. In contrast to DEHP it was  neither toxic
as to fertility nor as to development in animal studies. DINCH is
used in sensitive applications such as toys (Janssen and Bremmer,
2009) or medical devices (SCENIHR, 2008). DINCH is approved
for the use in plastic materials for food packaging (Regulation
(EU) No 1935/2004) and has also been listed in Regulation (EU)
No 10/2011 on plastic materials and articles intended to come
into contact with food without a speciﬁc migration limit (FCM
substance No. 775). According to the manufacturer, the pro-
duction volume was  200,000 t per year in 2014. Biomarkers for
measuring DINCH include oxidation products of the alkyl side
chain of the monoester MINCH: Cyclohexane-1,2-dicarboxylic
acid-mono(hydroxy-isononyl) ester (OH-MINCH), cyclohexane-
1,2-dicarboxylic acid-mono(carboxy-isooctyl) ester (cx-MINCH)
and cyclohexane-1,2-dicarboxylic acid-mono(oxo-isononyl) ester
(oxo-MINCH). Because oxo-MINCH has been predominantly
described in semi-quantitative terms, and only recently an ana-
lytical standard has been developed synthetically, the focus has
so far been on the analysis of OH-MINCH and cx-MINCH. These
two biomarkers differ considerably regarding their elimination
half-life. Analysis is performed after enzymatic hydrolysis by
means of an on-line HPLC–MS/MS method. Quantiﬁcation by
isotope dilution leads to LOQ (limit of quantiﬁcation) values for
the oxidized metabolites close to 0.05 g/l (Schütze et al., 2012).
For the derivation of the HBM I values the following parameters
were used:
• TDI value: 1 mg/kg bw/day (EFSA, 2006),
• quotient of the averaged molecular weight of the metabolites and
the molecular weight of DINCH: 0.75,
• urinary excretion factor (fue(48 h)): 0.1276 for both metabolites
(Koch et al., 2013),
• volume of urine, children: 0.03 l/kg bw/day,
• volume of urine, adults: 0.02 l/kg bw/day.
4.2.1. Calculation of HBM I values (urine)
HBM I (OH-MINCH + cx-MINCH) children: 1 × 0.75 × 0.1276/0.03
= 3.190, rounded 3 mg/l
HBM I (OH-MINCH + cx-MINCH) adults: 1 × 0.75 × 0.1276/0.02
= 4.785, rounded 4.5 mg/l (Kommission HBM, 2014d)
First results of the analysis of DINCH metabolites in 24 h urine
samples from the German Environmental Specimen Bank show that
the body burden of the test persons was  well below the HBM I value
in 2012 (Schütze et al., 2014).
4.3. HBM I values for the sum of DPHP metabolites oxo-MPHP
and OH-MPHP
DPHP (di(2-propylheptyl) phthalate or bis(2-propylheptyl)
benzene-1,2-dicarboxylate) is a plasticiser for plastic materials
and was developed as a technological alternative to diisodecyl
phthalate (DIDP). These two  phthalates differ in the structure of
their side chains. The DPHP side chain is largely based on 2-
propylheptane-1-ol, other components of the side chain include 4-
and 5-methyl-2-propylhexane-1-ol. Due to its low volatility, DPHP
is mainly used in soft PVC articles such as rooﬁng and covering
tarpaulins, cable and wire insulation materials as well as vehicle
interior furnishings. So far, no assessment by the European Food
Safety Authority, EFSA, is available for DPHP. Consequently, DPHP is
not listed under Regulation (EU) No. 10/2011 and therefore, cannot
be used in the food sector. Biomarkers of exposure are oxo-MPHPes for emerging substances, inventory of reference and HBM
omonitoring Commission. Int. J. Hyg. Environ. Health (2016),
(oxo-mono(propylheptyl) phthalate, fue: 13.5%) and OH-MPHP
(hydroxy-mono(propylheptyl)phthalate, fue: 10.7%) (Leng et al.,
2014). The elimination of metabolites was  tested in male subjects.
Neither age-speciﬁc differences nor a dependency, if any, of the
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etabolism on the level of exposure were examined until now. For
he analysis of DPHP metabolites in human urine a newly developed
peciﬁc method is available that is described in detail elsewhere
Gries et al., 2012). The limit of detection for the metabolites is
etween 0.05 and 0.1 g/l and the limit of quantiﬁcation is between
.15 and 0.3 g/l. For the derivation of the HBM I values the HBM
ommission selected a subchronic feeding study with rats as piv-
tal study (BASF, 1995), showing a NOAEL of 39 (rounded 40) mg/kg
w/day. The relevant effects are those on the thyroid and the pitu-
tary gland (BfR, 2011). Taking into account a total assessment
actor of 200 (2 for the adjustment of the study duration: sub-
hronic → chronic, 10 for the intraspecies variability, and 10 for the
nterspecies variability), a safe external exposure (TDI-like value)
f 0.2 mg/kg bw/day can be assumed.
For the derivation of the HBM I values the following parameters
ere used:
TDI-like value: 0.2 mg/kg bw/day,
ratio of the averaged molecular weight of the metabolites to the
molecular weight of DPHP: 0.72,
urinary excretion factor (fue(48 h)): 0.24 for the metabolites oxo-
and OH-MPHP,
volume of urine, children: 0.03 l/kg bw/day,
volume of urine, adults: 0.02 l/kg bw/day.
.3.1. Calculation of HBM I values (urine)
HBM I (oxo- + OH-MPHP), children: 0.2 × 0.72 × 0.24/0.03
 1.152 mg/l (rounded: 1 mg/l)
HBM I (oxo- + OH-MPHP), adults: 0.2 × 0.72 × 0.24/0.02
 1.728 mg/l (rounded: 1.5 mg/l) (Kommission HBM, 2015b).
.4. HBM I values for the DEHTP metabolite 5cx-MEPTP
Di(2-ethylhexyl) terephthalate or bis(2-ethylhexyl) terephtha-
ate (DEHTP) is used as plasticiser for PVC products and substitutes
ncreasingly other plasticisers which are classiﬁed as toxic to
eproduction. Within the framework of REACH-registration DEHTP
ounts as high production volume chemical with a total tonnage
f 10,000–100,000 tpa. It is, according to currently available data,
ot genotoxic or carcinogenic (ECHA, 2016). DEHTP did not show
ntiandrogenic properties (Furr et al., 2014), and no reproduc-
ive toxicity could be seen in animal studies (ECHA, 2016). The
eroxisome proliferating potential has been reported to be very
eak (ECHA, 2016). The European Food Safety Authority (EFSA,
008) derived a TDI value of 1 mg/kg bw/day based upon a 2-year
ombined toxicity/carcinogenicity study (Deyo, 2008); the most
ensitive endpoints observed were effects on the retina and the
asal turbinates.
The HBM Commission based its derivation of the HBM I val-
es for DEHTP also onto the endpoint “effects on the retina” but
sed instead of the NOAEC the BMDL10 of 54 mg/kg bw/day, as NSF
nternational (2012) did for its derivation of an oral RfD. A factor
f 10 each to account for intraspecies and interspecies variability
as selected to receive a TDI-like value of 0.54 mg/kg bw/day. An
dditional factor of 3 used by NSF International (2012) for database
eﬁciencies was not considered necessary. For the purpose of
uman biomonitoring a new sensitive HPLC–MS/MS method with
nline sample clean-up and isotope dilution (Lessmann et al.,
016a,b) has been established. The limit of quantiﬁcation is 0.2 g/l
or 5cx-MEPTP (1-mono(2-ethyl-5-carboxyl-pentyl) benzene-1,4
icarboxylate), the main speciﬁc urinary metabolite of DEHTP on
hich human biomonitoring should rely on.Please cite this article in press as: Apel, P., et al., New HBM valu
values in force, and working principles of the German Human Bi
http://dx.doi.org/10.1016/j.ijheh.2016.09.007
5cx-MEPTP represented in an oral study with three volunteers
bout 13% (48 h, mean) of the applied dose in urine, followed by
OH-MEHTP (mean: 1.8%), 5oxo-MEHTP (mean: 1.0%) and 2cx-
MHTP (0.3%) (Lessmann et al., 2016a,b). PRESS
 Environmental Health xxx (2016) xxx–xxx
For the derivation of the HBM I values the following parameters
were used:
• TDI-like value: 0.54 mg/kg bw/day,
• ratio of the molecular weight of the metabolite 5cx-MEPTP to the
molecular weight of DEHTP: 308.33/390.56 = 0.79
• urinary excretion factor (fue(48 h)): 0.1295 for the metabolite
5cx-MEPTP
• volume of urine, children: 0.03 l/kg bw/day,
• volume of urine, adults: 0.02 l/kg bw/day.
4.4.1. Calculation of HBM I values (urine)
HBM I (5cx-MEPTP), children: 0.54 × 0.79 × 0.1295/0.03
= 1.84 mg/l (rounded: 1.8 mg/l)
HBM I (5cx-MEPTP), adults: 0.54 × 0.79 × 0.1295/0.02 = 2.76 mg/l
(rounded: 2.8 mg/l) (publication projected).
4.5. HBM I value for HBCDD
Hexabromocyclododecane (HBCDD) has up to now mainly been
used as ﬂame retardant in thermal insulation foams and in tex-
tile coatings. Evidence is provided that HBCDD occurs in house
dust, mother milk, human blood, and fatty tissue. EFSA (2011)
identiﬁed neurodevelopmental effects on behaviour as the critical
endpoint of toxicological studies, and derived a benchmark dose
lower conﬁdence limit for a benchmark response of 10% (BMDL10)
of 0.93 mg/kg bw (single oral administration of HBCDD as a mixture
of the three diastereoisomers alpha, beta, and gamma  HBCDD). In
accordance with the EFSA Panel on Contaminants in the Food Chain
(2011) the HBM Commission considers the study of Eriksson et al.
(2006) as key study and the resulting BMDL10 as POD  for the deriva-
tion of the HBM I value. The available toxicokinetic data suggest that
orally administered HBCDD is easily absorbed and accumulates in
lipid tissue. Because the elimination kinetics of HBCDD in rodents
and humans differ, external dose levels of HBCDD associated with
toxic effects in animals cannot be simply extrapolated for the risk
assessment in humans. Instead, the internal body burden provides
a more appropriate dose metric for a direct comparison of effects
in animals and humans. On the basis of a proven oral absorption
in rodents of 85%, the body burden at the BMDL10 is 0.79 mg/kg
bw.  This value of 0.79 mg/kg bw has to be divided by a factor of
0.32 (women: 32% fatty tissue) to receive the tolerable internal
dose for the lipid compartment of the body. With a total AF of 8
for differences in toxicodynamics (intraspecies factor = 3.2, inter-
species factor = 2.5) the HBM I value for total HBCDD was  ﬁnally set
at 0.3 g/g lipid (1.6 g/l plasma) (Kommission HBM, 2015c).
4.6. HBM values for the sum of NMP  metabolites 5-HNMP and
2-HMSI
N-methyl-2-pyrrolidone (NMP) is used as a solvent in many
technical applications. The general population may  be exposed
to NMP  from the use as ingredient in paint and grafﬁti remover,
indoors also from the use in paints and carpeting. Because of its
developmental toxicity, NMP  is classiﬁed as substance of very
high concern and is listed as candidate for authorisation under
REACH (ECHA, 2013; National Institute for Public Health and the
Environment (RIVM), 2013). The developmental effects are also
considered as the critical effects for the HBM value derivation. The
NOAEL of 125 mg/kg bw/day of an oral study on developmental
toxicity with rats (Saillenfait et al., 2002) was chosen as POD and
a total assessment factor of 300 was applied to calculate a toler-es for emerging substances, inventory of reference and HBM
omonitoring Commission. Int. J. Hyg. Environ. Health (2016),
able external dose or TDI-like value of 0.42 mg/kg bw/day (AF 10
for intraspecies variability, AF 10 for interspecies variability, and
AF 3 as additional factor having regard to the results of a sec-
ond study (Sitarek et al., 2012)). 5-Hydroxy-NMP (5-HNMP) and
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-hydroxy-N-methylsuccinimide (2-HMSI) were identiﬁed as main
etabolites in urine and their excretion is used to estimate the
nternal exposure with NMP.
For the derivation of the HBM values the following parameters
ere used:
TDI-like value: 0.42 mg/kg bw/day,
ratio of the averaged molecular weight of the metabolites and the
molecular weight of NMP: 1.23,
urinary excretion factor (fue): 0.65 for the metabolites 5-HNMP
and 2-HMSI (Åkesson and Jönsson,1997),
volume of urine, children: 0.03 l/kg bw/day,
volume of urine, adults: 0.02 l/kg bw/day.
.6.1. Calculation of HBM values (urine)
HBM I (5-HNMP + 2-HMSI), children: 0.42 × 1.23 × 0.65/0.03
 11.2 mg/l (rounded: 10 mg/l)
HBM I (5-HNMP + 2-HMSI), adults: 0.42 × 1.23 × 0.65/0.02
 16.8 mg/l (rounded: 15 mg/l)
The HBM II values were set at 30 mg/l for children and 50 mg/l
or adults (Kommission HBM, 2015d).
.7. HBM values for the sum of NEP metabolites 5-HNEP and
-HESI
N-ethyl-2-pyrrolidone (NEP), a polar aprotic solvent, is used
n many applications as substitute for the structural analogue N-
ethyl-2-pyrrolidone (NMP), e.g. for surface coatings, in cleaning
gents and paint strippers. Inhalation can be assumed to be the
ost important route of exposure, followed by the dermal route.
onitoring studies indicate that individuals within the general
ublic, without occupational exposure, may  be exposed to NEP to
n extent which is comparable to NMP  (Käfferlein et al., 2013).
xposure to NEP can be quantiﬁed by determining the excre-
ion of its urinary metabolites 5-hydroxy-N-ethyl-2-pyrrolidone
5-HNEP) and 2-hydroxy-N-ethylsuccinimide (2-HESI) (Koch et al.,
014). A speciﬁc method already available for the analysis and
uantiﬁcation of NEP metabolites in urine (Schindler et al., 2012)
as been enhanced for the biomonitoring of the general popula-
ion: following solid phase extraction, separation is performed by
as chromatography, and the detection is carried out by using tan-
em mass spectrometry with quantiﬁcation via isotope dilution.
oth for 5-HNEP and 2-HESI, the limit of detection (LOD) is 1 g/l,
nd the limit of quantiﬁcation (LOQ) is 2.5 g/l (Bader et al., 2014).
For the derivation of the HBM values, the HBM Commission eval-
ated different studies and toxicological endpoints. Finally the HBM
ommission decided on a subchronic feeding study with rats as piv-
tal study (Kaspers et al., 2006) and on the BMDL05 and the BMD10
or the endpoint “reduced grasp intensity” as points of departure
POD). With a total assessment factor of 200 (2 for study duration
djustment, 10 for intraspecies variability, and 10 for interspecies
ariability) the following values were received:
BMDL05 as POD for HBM I: 90 mg/kg bw/day → 0.45 mg/kg
w/day (TDI-like value)
BMD10 as POD for HBM II: 250 mg/kg bw/day → 1.25 mg/kg
w/day
For the derivation of the HBM values the following parameters
ere used:
TDI like value: 0.45 mg/kg bw/day,
value for HBM II value derivation: 1.25 mg/kg bw/day,Please cite this article in press as: Apel, P., et al., New HBM valu
values in force, and working principles of the German Human Bi
http://dx.doi.org/10.1016/j.ijheh.2016.09.007
ratio of the averaged molecular weight of the metabolites and the
molecular weight of NEP: 1.2,
urinary excretion factor (fue(96 h)): 0.505 for the metabolites 5-
HNEP and 2-HESI (Koch et al., 2014), PRESS
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• volume of urine, children: 0.03 l/kg bw/day,
• volume of urine, adults: 0.02 l/kg bw/day.
4.7.1. Calculation of HBM values (urine)
HBM I (5-HNEP + 2-HESI) children: 0.45 × 1.2 × 0.505/0.03
= 9.09 mg/l (rounded: 10 mg/l)
HBM I (5-HNEP + 2-HESI) adults: 0.45 × 1.2 × 0.505/0.02
= 13.64 mg/l (rounded: 15 mg/l)
HBM-II (5-HNEP + 2-HESI) children: 1.25 × 1.2 × 0.505/0.03
= 25.25 mg/l (rounded: 25 mg/l)
HBM-II (5-HNEP + 2-HESI) adults: 1.25 × 1.2 × 0.505/0.02
= 37.88 mg/l (rounded: 40 mg/l)
The HBM I values refer to the endpoint “reduced grasp intensity”
but are also protective for developmental toxicity. Measurements
at and above the HBM II value give cause for concern, especially for
pregnant women. Air measurements to detect and eliminate the
source of exposure can be useful. The possibility of skin absorp-
tion from use of cleaning agents and paint strippers should also be
traced. The values apply to the evaluation of single substances. In
practice, it has to be assumed that exposure to NEP may  always
occur simultaneously with and in addition to NMP. Due to the very
similar toxicological proﬁles of these two substances, in particular
regarding developmental toxicity and teratogenic effects, a mixed
exposure to both substances has to be taken into account in the
evaluation of ﬁndings (Kommission HBM, 2015e).
4.8. HBM I values for triclosan
Triclosan is a lipophilic, broad spectrum antimicrobial agent
which is used in many personal care products like toothpaste,
shower gel, and in consumer products like textiles and toys. The
HBM I value for triclosan is based on the BE value derivation for tri-
closan (Krishnan et al., 2010). The NOAEL of 12 mg/kg bw/day used
as POD for the calculation of both, the BE and the HBM I value, is
obtained from an oral study over 2 years with rats (DeSalva et al.,
1989) and refers to the endpoints haematotoxicity and decrease
in spleen weight. The NOAEL has been conﬁrmed by the Scien-
tiﬁc Committee on Consumer Safety of the European Commission
(SCCS) in 2011. Application of a total assessment factor of 100, mul-
tiplication with the fue of 0.54 (Sandborgh-Englund et al., 2006)
and division by the value for the urine volume of 0.02 l/kg bw/day
(adults) or 0.03 l/kg bw/day (children) leads to HBM I values of
3.2 mg  triclosan/l for adults and 2.2 mg  triclosan/l for children
(Kommission HBM, 2015f).
For the period of 1995–2012 the time trend of triclosan in
the urine of the German general population was  established by
analysing 660 urine samples of the German environmental spec-
imen bank from the years 1995, 1997, 1999, 2001, 2003, 2005,
2006, 2007, 2008, 2009 and 2012. The samples came predominantly
from students of the university of Münster aged 20–30. From each
year 30 samples of males and 30 samples of females were ana-
lysed. Triclosan could be detected in all 660 samples measured. No
differences between males and females could be determined. The
median concentration of Triclosan in urine ranged from 0.50 g/l
to 3.20 g/l for each separate year. A time trend was  not detectable
for the survey period, although a voluntary waiver declaration of
the producers exists (Kommission HBM, 2015f).
4.9. HBM I values for 2-mercaptobenzothiazole (2-MBT)
2-Mercaptobenzothiazole (2-MBT) is mainly used as a vulcani-es for emerging substances, inventory of reference and HBM
omonitoring Commission. Int. J. Hyg. Environ. Health (2016),
sation accelerator in the production of rubber. Other applications
are as a fungicide in paints and varnishes as well as for the exter-
nal treatment of animals. Because of its manifold applications in
consumer products, for example in soothers, exposure of the
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eneral population to 2-MBT can’t be excluded. For the toxico-
ogical evaluation of a possible body burden the HBM Commission
erived HBM I values for 2-MBT in the urine of children and adults.
he no observed adverse effect level of 94 mg/kg bw/day from a
ubchronic oral study with mice was used as POD (NTP (National
oxicology Program), 1988; SCF, 2000; BfR, 2008). The relevant
ndpoint for this value was the increased liver weight. After con-
ideration of a total assessment factor of 350 (2 for study duration
djustment: subchronic to chronic, 10 for intraspecies variability,
nd 17.5 for interspecies variability), a tolerable daily intake of
.3 mg/kg bw/day was deduced for humans. Having furthermore
egard to the percentage of 2-MBT and its glucuronide excreted in
rine (45%) and the body weight proportional urine volume, the
ollowing HBM I values could be derived:
HBM I (children): 4.5 mg  2-MBT/l urine,
HBM I (adults): 7 mg 2-MBT/l urine (Kommission HBM, 2015g).
.10. HBM I values for the sum of 4-MBC metabolites 3-4CBHC
nd 3-4CBC
The substance 3-(4-methylbenzylidene) camphor (4-MBC, CAS-
o. 36861-47-9 as well as 38102-62-4) is used as UV-ﬁlter in
osmetics, mainly in sunscreen lotions. National as well as Euro-
ean evaluations are available for the substance, especially from
he Scientiﬁc Committee on Consumer Products (SCCP, 2008). The
CCP did not derive a TDI value, but used for a margin of safety
MoS) assessment a NOAEL of 25 mg/kg bw/day based on effects
n the thyroid gland of rats in a subchronic oral study (Kieser
t al., 1984). Newer studies, however, indicate lower NOAEL val-
es (Maerkel et al., 2007; Durrer et al., 2007; Hofkamp et al., 2008;
chlumpf et al., 2008; Faass et al., 2009). The HBM Commission
ocused on the one generation study with rats of Durrer et al.
2007) which resulted in a NOAEL of 0.7 mg/kg bw/day, correspond-
ng to a tolerable daily intake of 0.01 mg/kg bw. Humans excrete
0% of the available systemic proportion of administered 4-MBC in
he urine whereupon 80% are assigned to the main metabolite 3-
4-carboxybenzylidene)-6-hydroxycamphor (3-4CBHC) and 20% to
-(4-carboxybenzylidene) camphor (3-4CBC). A sensitive method
or the analysis of these metabolites in urine has been developed
ith LOQs of 1 g/l for 3-4CBHC and 1.5 g/l for 3-4CBC. The HBM
ommission established for the metabolite 3-4CBHC HBM I values
f 0.38 mg/l urine for adults and 0.25 mg/l urine for children. The
BM I values for 3-4CBC were set at 0.09 mg/l urine for adults and
.06 mg/l urine for children.
The rounded HBM I values for the sum of the metabolites 3-4CBHC
nd 3-4CBC are accordingly 0.5 mg/l urine for adults and 0.3 mg/l
rine for children (Kommission HBM, 2016b).
.11. HBM I values for perﬂuorooctanoic acid (PFOA) und
erﬂuorooctanesulfonic acid (PFOS) in blood plasma
Based on an assessment of the literature on human epidemiolog-
cal studies and on animal studies the HBM Commission decided to
et HBM I values for PFOA and PFOS in blood plasma at 2 ng PFOA/ml
nd 5 ng PFOS/ml (Kommission HBM, 2016c, detailed publication
n preparation).
The method chosen for the HBM I value derivation rests upon
uman data and critical effects. Epidemiological studies point, for
nstance, to an association between the exposure to PFOA or PFOS
nd risks of delayed fertility or also of infertility. Taking the reported
pper values of the quantiles without signiﬁcant effects each as POD
he resulting values for PFOA are constantly below 5 ng/ml plasma,Please cite this article in press as: Apel, P., et al., New HBM valu
values in force, and working principles of the German Human Bi
http://dx.doi.org/10.1016/j.ijheh.2016.09.007
ith a trend to 2 ng/ml (Fei et al., 2009; Whitworth et al., 2012;
élez et al., 2015). Estimates for PFOS are below 30 ng/ml plasma,
n the lowest case at 17 ng/ml (Fei et al., 2009; Whitworth et al.,
012). Recently, a meta-analysis was published which shows a PRESS
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signiﬁcant link between fetal growth and exposure to PFOA
(Johnson et al., 2014). Furthermore, Fitz-Simon et al. (2013)
observed in a longitudinal study an association of raised choles-
terol concentrations with increasing PFOA or PFOS exposure. Geiger
et al. (2014) concluded from their studies among US children and
adolescents at the age of 6–18 years that the increasing internal
exposure to PFOA or PFOS is signiﬁcantly associated with the total
cholesterol and LDL-cholesterol (POD for PFOA: 4.7 ng/ml, POD for
PFOS: 22 ng/ml). In addition, the immune response can be impaired.
Grandjean and Budtz-Jørgensen (2013) found with their bench-
mark dose-modelling associations of a PFOA or PFOS exposure at
a very low level and a decreased immune response of children
which were vaccinated with Tetanus or Diphtheria (POD for PFOA:
0.3 ng/ml (BMDL5), POD for PFOS: 1.3 ng/ml (BMDL5)).
Analogies between animal and epidemiological studies enhance
the plausibility that the effects chosen as endpoints are relevant.
Thus, mammary epithelial growth has turned out to be a very sen-
sitive marker of developmental toxicity for the offspring of orally
PFOA-treated mouse dams. Inhibitory effects have been observed at
285 ng PFOA/ml blood serum (LOAEL) (Macon et al., 2011). Assum-
ing an assessment factor of 10 to extrapolate from LOAEL to NOAEL,
a corresponding NOAEL would be in the range of 29 ng PFOA/ml
serum. Extrapolated to humans does that mean that no effects on
the sexual differentiation have to be anticipated up to a concentra-
tion of 1 ng/ml serum. PFOS suppresses the humoral immunity in
male mice at very low doses. Peden-Adams et al. (2008) reported a
LOAEL of 1.66 g PFOS/kg body weight (oral dose). The blood con-
centration in these animals was  91.5 ng PFOS/g serum. The NOAEL
was about 10 times lower, the corresponding blood concentration
was 17.8 ng PFOS/g serum. In female mice, the NOAEL was about 20-
fold higher compared to the male animals. Extrapolated to humans
does that mean that no effects on the immune system have to be
expected at a concentration of 1–10 ng/ml serum.
In summary, the HBM Commission rates effects in the subse-
quent areas as well proven, relevant, and signiﬁcantly associated
with an exposure to PFOA and/or PFOS:
1. Fertility and pregnancy
a) Time to wanted pregnancy
b) Waiting period for pregnancies > 1 year
c) Gestosis and gestational diabetes
2. Weight of newborns at birth
3. Lipid metabolism
4. Immunity after vaccination, immunological development
5. Hormonal development, age at puberty/menarche
6. Thyroid metabolism
7. Onset of menopause
The literature reports quantile contrasts, BMD derivations or
regression analyses for continuous endpoints (e.g. birth weights,
fat metabolism, sex hormones) differently. Regarding quantile con-
trasts, the HBM Commission has selected the upper bounds of
the quantiles without signiﬁcant effects. This is in line with the
approach of the HBM I value, marking a level of protection at which
“adverse health effects are not expected”. BMD  modelling usually
leads to lower POD, but cannot be carried out consistently with the
available data.
The Commission points out that the sample sizes and concen-
tration ranges reported in different studies as well as the chosen
quantiles and confounders cannot be evaluated using a standard
procedure. The Commission has therefore decided to use the result-
ing POD ranges as a basis for deriving the HBM I value.es for emerging substances, inventory of reference and HBM
omonitoring Commission. Int. J. Hyg. Environ. Health (2016),
The data available do not appear to show proof of genotoxicity
of PFOA and PFOS.
Results of the analysis of 258 cryo-conserved plasma samples
of the German environmental specimen bank (age group 20–29
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Table 2
Provisional reference values (RV95) for parabens in urine (Kommission HBM, 2014c).
Parameter Population group RV95
Methylparaben Women
Men
400 g/l
240 g/l
Ethylparaben Women
Men
50 g/l
25 g/l
Propylparaben Women
Men
100 g/l
50 g/l
Butylparaben Women
Men
20 g/l
10 g/l
T
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ears) allow a comparison with the derived HBM I values and reﬂect
ow far voluntary and regulatory mitigation measures took effect
ntil 2010 (Schröter-Kermani et al., 2013). Since 1986 the median
f the PFOA concentration had been ﬂuctuating between 4.8 and
.3 ng/ml before it decreased in 2008. After an increase from 1982
o 1986, the median of the PFOS concentration leveled off at 20-
4 ng/ml until the late 1990s. Since 2001 the median of the PFOS
oncentration had been decreasing continuously to 4 ng/ml in 2010.
urther data on the exposure of children (aged between 3 and 17)
o PFOA and PFOS are being collected in the context of the current
erman Environmental Survey 2014–2017, GerES V.
. Reference values
In order to be able to describe the background exposure of the
opulation and its temporal development the HBM Commission
erives reference values by means of statistical methods. These
eference values are based on the 95% conﬁdence interval of the
5th percentile of the concentration of a chemical substance in the
atrix obtained from a reference population. Preferably, reference
alues are derived from data obtained from a representative popu-
ation sample in the context of the German Environmental Survey,
erES. They allow a uniform assessment of the body burden at
he German national level, and are indispensable to demonstrate
hether a certain exposure level exceeds the background exposurePlease cite this article in press as: Apel, P., et al., New HBM valu
values in force, and working principles of the German Human Bi
http://dx.doi.org/10.1016/j.ijheh.2016.09.007
evel, e.g. accident-related exposures. Because of their statisti-
al nature, reference values cannot serve to asses health risks.
eference values are checked continuously and are updated if new
nformation becomes available.
able 3
rovisional reference values (RV95) for PCB in blood.
Previous values update
Parameter Population/Age
group [years]
Year of the
study
RV95 in g/l
whole blood
Year of the
study
PCB 138 7–14a 2003/06 0.3
18–19b 1997/99 0.4 2010c
20–29b 1997/99 0.6 2010c
30–39b 1997/99 0.9 2010c
40–49b 1997/99 1.4 2010c
50–59b 1997/99 1.7 2010c
60–69b 1997/99 2.2 2010c
PCB  153 7–14a 2003/06 0.4
18–19b 1997/99 0.6 2010c
20–29b 1997/99 0.9 2010c
30–39b 1997/99 1.6 2010c
40–49b 1997/99 2.2 2010c
50–59b 1997/99 2.8 2010c
60–69b 1997/99 3.3 2010c
PCB  180 7–14a 2003/06 0.3
18–19b 1997/99 0.3 2010c
20–29b 1997/99 0.6 2010c
30–39b 1997/99 1 2010c
40–49b 1997/99 1.6 2010c
50–59b 1997/99 2.1 2010c
60–69b 1997/99 2.4 2010c
∑
PCB 7–14a 2003/06 1
(138 + 153 + 180) 18–19b 1997/99 1.1 2010c
20–29b 1997/99 2 2010c
30–39b 1997/99 3,2 2010c
40–49b 1997/99 5.1 2010c
50–59b 1997/99 6.4 2010c
60–69b 1997/99 7.8 2010c
a Source of data: German Environmental Survey for Children 2003/06.
b Source of data: German Environmental Survey 1997/99.
c Source of data: German environmental specimen bank.Isobutylparaben Women
Men
10 g/l
3 g/l
During the last 3 years the HBM Commission deﬁned provi-
sional reference values for MAA  (0.3 mg  MAA/l) (Kommission HBM,
2014b) and for several parabens (Table 2, Kommission HBM, 2014c)
in the urine of the German population.
Parabens are the alkyl-, isoalkyl-, and benzylester of 4-hydroxy-
benzoic acid and their sodium salts. They are used predominantly
as preservatives. With the exception of the data from the German
environmental specimen bank, the sample size of available data
sets is too small for a reliable determination of the 95% quan-
tiles. This is why reference values for females and males were
derived on the basis of the data from the German environmen-
tal specimen bank. These reference values are provisional ones
because they are lacking representativeness with regard to the
selection of test persons and a regional and demographic stratiﬁ-es for emerging substances, inventory of reference and HBM
omonitoring Commission. Int. J. Hyg. Environ. Health (2016),
cation. The data pool of the German environmental specimen bank
comprises 660 data sets (referring to 24 h urine) with balanced sizes
of sex groups (N = 330 each). The test person’s age varied between
Men/Women
g/l whole
blood
Men  g/l
plasma
Women g/l
plasma
Men  g/g
lipid
Women g/g
lipid
0.13 0.24 0.22 0.035 0.032
0.20 0.36 0.33 0.052 0.048
0.45 0.82 0.75 0.12 0.11
0.70 1.3 1.2 0.18 0.17
0.85 1.5 1.4 0.22 0.20
1.10 2.0 1.8 0.29 0.26
0.20 0.36 0.33 0.052 0.048
0.30 0.54 0.50 0.078 0.071
0.80 1.5 1.3 0.21 0.19
1.10 2.0 1.8 0.29 0.26
1.40 2.5 2.3 0.36 0.33
1.65 3.0 2.8 0.43 0.39
0.10 0.18 0.17 0.026 0.024
0.20 0.36 0.33 0.052 0.048
0.50 0.91 0.83 0.13 0.12
0.80 1.5 1.3 0.21 0.19
1.05 1.9 1.8 0.27 0.25
1.2 2.2 2.0 0.31 0.29
0.37 0.67 0.61 0.10 0.087
0.67 1.2 1.1 0.17 0.16
1.6 2.9 2.7 0.42 0.38
2.6 4.6 4.3 0.66 0.61
3.2 5.8 5.3 0.83 0.76
3.9 7.1 6.5 1.0 0.93
Please cite this article in press as: Apel, P., et al., New HBM values for emerging substances, inventory of reference and HBM
values in force, and working principles of the German Human Biomonitoring Commission. Int. J. Hyg. Environ. Health (2016),
http://dx.doi.org/10.1016/j.ijheh.2016.09.007
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Table  4
Reference values (RV95) for antimony, arsenic, cadmium, lead, mercury, nickel, thallium, platinum, uranium in urine or blood (according to Schulz et al., 2011).
Parameter and matrix Population group (age range in years) Study period RV95a
Antimony in urine Children (3–14) 2003–2006 0.3 g/l
Arsenic in urine Children who  did not eat ﬁsh 48 h prior to sample collection (3–14) 2003–2006 15.0 g/l
Adults who did not eat ﬁsh 48 h prior to sample collection (18–69) 1997–1999 15.0 g/l
Cadmium in urine Non-smoking children (3–14) 2003–2006 0.2 g/l
Non-smoking adults (18–69) 1997–1999 0.8 g/l
Cadmium in blood Non-smoking children (3–14) 2003–2006 <0.3 g/lb
Non-smoking adults (18–69) 1997–1999 1.0 g/l
Lead  in blood
Children (3–14) 2003–2006 35 g/l
Women  (18–69) 1997–1999 70 g/l
Men  (18–69) 1997–1999 90 g/l
Mercury in urine
Children without dental amalgam ﬁllings (3–14) 2003–2006 0.4 g/l
Adults without dental amalgam ﬁllings (18–69) 1997–1999 1.0 g/l
Mercury in blood
Children who  ate ﬁsh ≤ 3 times per month (3–14) 2003–2006 0.8 g/l
Adults who ate ﬁsh ≤ 3 times per month (18–69) 1997–1999 2.0 g/l
Nickel in urine
Children (3–14) 2003–2006 4.5 g/l
Adults (not a strictly representative sample) Not speciﬁed 3.0 g/l
Platinum in urine Adults without dental inlays, crowns or bridge elements made of precious metal (18–69) 1997–1999 0.01 g/l
Thallium in urine Children (3–14) 2003–2006 0.6 g/l
Adults (20–29)c 2000–2008 0.5 g/l
Uranium in urine Children (3–14) 2003–2006 0.04 g/l
Adults  (not a strictly representative sample) 2001–2003 0.03−0.06 g/ld
a Uncertainty of analysis must be taken into account.
b No reference value, but if there should be analytically reliable and conﬁrmed concentrations of Cd in whole blood above the level of 0.3 g/l, a special exposure must be
expected such as active smoking, i.e.
c Data obtained from the German Environmental Specimen Bank (ESB) for human tissues.
d This background exposure level should be used for orientation unless data are available from a representative population sample.
Table 5
Reference values (RV95) for chlorophenols in urine of children and adults and pentachlorophenol in serum of adults (according to Schulz et al., 2011).
Parameter Population group (age range in
years)
Study period RV95a
2-Monochlorophenol Children (3–14) 2003–2006 7.0 g/l
4-Monochlorophenol Children (3–14)
Adults (18–69)
2003–2006
1997–1999
15.0 g/l
15.0 g/l
2,4-Dichlorophenol Children (3–14)
Adults (18–69)
2003–2006
1997–1999
2.0 g/l
3.0 g/l
2,5-Dichlorophenol Children (3–14)
Adults (18–69)
2003–2006
1997–1999
6.0 g/l
20.0 g/l
2,6-Dichlorophenol Children (3–14)
Adults (18–69 years)
2003–2006
1997–1999
<0.3 g/lb
<0.3 g/lb
2,3,4-Trichlorophenol Children (3–14)
Adults (18–69)
2003–2006
1997–1999
<0.3 g/lb
<0.3 g/lb
2,4,5- Children (3–14) 2003–2006 0.5 g/l
Trichlorophenol Adults (18–69) 1997–1999 1 g/l
2,4,6-  Children (3–14) 2003–2006 0.7 g/l
Trichlorophenol Adults (18–69) 1997–1999 1.5 g/l
2,3,4,6- Children (3–14) 2003–2006 <0.3 g/lb
Tetrachlorophenol Adults (18–69) 1997–1999 1.0 g/l
Pentachlorophenol (PCP) in urine Children (3–14)
Adults (18–69) living in homes
without wood preservatives
2003–2006
1997–1999
2.0 g/lb
5.0 g/l
PCP  in serum Adults (not a strictly
representative sample)
1995–1996 12.0 g/l
a Uncertainty of analysis must be taken into account.
b No reference value, but if there are analytically reliable and conﬁrmed concentrations above the mentioned value, a special exposure must be expected.
Table 6
Reference values (RV95) for metabolites of organophosphate insecticides (DMP, DMTP, DMDTP, DEP, DETP) in urine (according to Schulz et al., 2011).
Parameter Population group (age range in years) Study period RV95a
DMP
Children (3–14) 2003–2006 75 g/l
General populationb 1998 135 g/l
DMTP
Children (3–14) 2003–2006 100 g/l
General populationb 1998 160 g/l
DMDTP Children (3–14) 2003–2006 10 g/l
DEP
Children (3–14) 2003–2006 30 g/l
General populationb 1998 16 g/l
DETP  Children (3–14) 2003–2006 10 g/l
a Uncertainty of analysis must be taken into account.
b Not a strictly representative sample; DMP: dimethylphosphate; DMTP: dimethylthiophosphate; DMDTP: dimethyldithiophosphate; DEP: diethylphosphate; DETP:
diethylthiophosphate.
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Table  7
Reference values (RV95) for metabolites of pyrethroid insecticides (cis-Cl2CA, trans-Cl2CA, 3-PBA) in urine (according to Schulz et al., 2011).
Parameter Population group (age range in years) Study period RV95a
cis-Cl2CA
Children (3–14) 2003–2006 1 g/l
General populationb 1998 1 g/l
trans-  Cl2CA
Children (3–14) 2003–2006 2 g/l
General populationb 1998 2 g/l
3-PBA
Children (3–14) 2003–2006 2 g/l
General populationb 1998 2 g/l
a Uncertainty of analysis must be taken into account.
b Not a strictly representative sample; cis-Cl2CA and trans-Cl2CA: cis- and trans-3-(2,2-dichlorovinyl)-2,2-dimethylcyclopropanecarboxylic acid; 3-PBA: 3-phenoxybenzoic
acid.
Table 8
Reference values (RV95) for metabolites of polycyclic aromatic hydrocarbons in urine of non-smoking children and of non-smoking adults (according to Schulz et al., 2011).
Parameter Population group (age range in years) Study period RV95a
1-Hydroxypyrene Non-smoking children (3–14)
Non-smoking adults (18–69)
2003–2006
1997–1999
0.5 g/l
0.5 g/l
1-Hydroxy-phenanthrene Non-smoking children (3–14) 2003–2006 0.6 g/l
2/9-Hydroxy-phenanthrene Non-smoking children (3–14) 2003–2006 0.4 g/l
3-Hydroxy-phenanthrene Non-smoking children (3–14) 2003–2006 0.5 g/l
4-Hydroxy-phenanthrene Non-smoking children (3–14) 2003–2006 0.2 g/l∑
Hydroxy-phenanthrene Non-smoking children (3–14) 2003–2006 1.5 g/l
aUncertainty of analysis must be taken into account.
Table 9
Reference values (RV95) for hexachlorocyclohexane (HCH) and hexachlorobenzene
(HCB) in whole blood of children and adults (according to Schulz et al., 2011, slightly
modiﬁed).
Parameter Population group
(age range in years)
Study period RV95a
-HCH 7–14
18–69
2003–2006
1997–1999
<0.1 g/lb
<0.1 g/lb
-HCH 7–14 2003–2006 0.1 g/l
18–19 1997–1999 0.3 g/l
20–29 1997–1999 0.3 g/l
30–39 1997–1999 0.3 g/l
40–49 1997–1999 0.3 g/l
50–59 1997–1999 0.5 g/l
60–69 1997–1999 0.9 g/l
HCB 7–14 2003–2006 0.2 g/l
18–19 1997–1999 0.4 g/l
20–29 1997–1999 0.5 g/l
30–39 1997–1999 1.0 g/l
40–49 1997–1999 2.5 g/l
50–59 1997–1999 3.3 g/l
60–69 1997–1999 5.8 g/l
a
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Table 10
Reference values (RV95) for 1,1-dichloro-2,2-bis(p-chlorophenyl) ethylene (DDE) in
whole blood of children and adults (according to Schulz et al., 2011).
Parameter Population group (age
range in years)
Study period RV95a
DDE 7–14 (West Germany) 2003–2006 0.7 g/l
7–14 (East Germany) 2003–2006 1.4 g/l
18–19 (West Germany) 1997–1999 1.5 g/l
18–19 (East Germany) 1997–1999 3 g/lb
20–29 (West Germany) 1997–1999 2 g/l
20–29 (East Germany) 1997–1999 5 g/l
30–39 (West Germany) 1997–1999 4 g/l
30–39 (East Germany) 1997–1999 11 g/l
40–49 (West Germany) 1997–1999 7 g/l
40–49 (East Germany) 1997–1999 18 g/l
50–59 (West Germany) 1997–1999 8 g/l
50–59 (East Germany) 1997–1999 31 g/l
60–69 (West Germany) 1997–1999 11 g/l
60–69 (East Germany) 1997–1999 31 g/lUncertainty of analysis must be taken into account.
b No reference value, but if there should be analytically reliable and conﬁrmed
oncentrations above the mentioned value, a special exposure must be expected.
0 and 30 years. The measurements are assigned to the years of
995–2012.
Furthermore the HBM Commission updated the reference val-
es for polychlorinated biphenyls (PCB) in blood of the German
opulation (Table 3, Kommission HBM, 2012, 2016d). This was nec-
ssary because the analysis of the time trend of PCB uptake via food
 the main exposure route for the general population − shows a
arked decrease for Germany. It could therefore be assumed that
CB body burdens have fallen. As current survey data represen-
ative of the population are not available, the HBM Commission
onsidered whether data from the analysis of samples from the
erman environmental specimen bank could be used for a pro-
isional update. It concluded that the dataset from the GermanPlease cite this article in press as: Apel, P., et al., New HBM valu
values in force, and working principles of the German Human Bi
http://dx.doi.org/10.1016/j.ijheh.2016.09.007
nvironmental specimen bank is suitable, at least for the age group
f 20–29, for estimating the change in blood PCB levels over time
nd the inﬂuence of exposure history and age. For the people aged
0–29 the HBM Commission sees a decrease in PCB concentrationsa Uncertainty of analysis must be taken into account.
b Based on the 95th percentile of the values from 28 subjects.
in plasma (congeners 138, 153, 180) to about a third (factor of 0.33)
in the period 1997–2010. The HBM Commission assumes that the
reduction is lower for older persons with a longer exposure his-
tory (factor of about 0.5). The assumption of a smaller reduction
in blood PCB levels among older age groups from the age of 30
years onwards is based on the fact that the PCB congeners con-
sidered have half- lives in plasma of about 10 years and that the
longer exposure history of these age groups, particularly the higher
rate of uptake during high-contamination years, results in a higher
body burden. The HBM Commission is aware of the uncertainties
associated with deriving the new PCB reference values through a
factor-based estimation. It sees the limited representativeness of
the data additionally included and the weaknesses of using mod-
elling. Nevertheless, based on a review of the current data situation
(Hardell et al., 2010) in conjunction with an analysis of time trends
of data from cross-sectional studies (Ritter et al., 2009, 2011; Quinn
et al., 2011; Quinn and Wania, 2012; Schettgen et al., 2011, 2015;es for emerging substances, inventory of reference and HBM
omonitoring Commission. Int. J. Hyg. Environ. Health (2016),
Fromme  et al., 2015) it considers it justiﬁed to lower the reference
values.
Table 3 lists the original RV95 values from 1997/99 together
with the recalculated provisional RV95 values for PCB concen-
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Table  11
Reference values (RV95) for aromatic amines in urine of non-smoking adults (according to Schulz et al., 2011).
Parameter Population group Study period RV95a
Aniline Non-smoking adultsb 2003–2004 14.5 g/l
o-Toluidine Non-smoking adultsb 2003–2004 0.20 g/l
m-Toluidine Non-smoking adultsb 2003–2004 0.25 g/l
p-Toluidine Non-smoking adultsb 2003–2004 1.25 g/l
o-Anisidine Non-smoking adultsb 2003–2004 1.10 g/l
3-Chloroaniline Non-smoking adultsb 2003–2004 0.25 g/l
4-Chloroaniline Non-smoking adultsb 2003–2004 1.00 g/l
3,4-Dichloroaniline Non-smoking adultsb 2003–2004 0.45 g/l
3,5-Dichloroaniline Non-smoking adultsb 2003–2004 4.30 g/l
a Uncertainty of analysis must be taken into account.
b Not a strictly representative sample.
Table 12
Reference values (RV95) for metabolites of phthalates in urine of children and adults (according to Schulz et al., 2011).
Phthalate Metabolite(s) in urine Population group (age range in years) Study period RV95a
DnBP MnBP Children (3–14) 2003–2006 300 g/l
Adults (20–29)b 2006/2008 70 g/l
DiBP  MiBP Children (3–14) 2003–2006 300 g/l
Adults (20–29)b 2006/2008 140 g/l
BBzP  MBzP Children (3–14) 2003–2006 75 g/l
Adults (20–29)b 2006/2008 15 g/l
DEHP  5-OH-MEHP + 5-oxo-MEHP Children (3–14) 2003–2006 280 g/l
Adults (20–29)b 2006/2008 50 g/l
DEHP  5-OH-MEHP Children (3–14) 2003–2006 160 g/l
Adults (20–29)b 2006/2008 30 g/l
DEHP  5-oxo-MEHP Children (3–14) 2003–2006 120 g/l
Adults (20–29)b 2006/2008 20 g/l
DEHP  5-cx-MEPP Children (3–14) 2003–2006 200 g/l
Adults (20–29)b 2006/2008 30 g/l
DiNP  Sum of 3 metabolites of DiNP Children (3–14) 2003–2006 140 g/l
Adults (20–29)b 2006/2008 60 g/l
DiNP  OH-MiNP Children (3–14) 2003–2006 50 g/l
Adults (20–29)b 2006/2008 20 g/l
DiNP  oxo-MiNP Children (3–14) 2003–2006 30 g/l
Adults (20–29)b 2006/2008 15 g/l
DiNP  cx-MiNP Children (3–14) 2003–2006 60 g/l
Adults (20–29)b 2006/2008 25 g/l
DnBP: di-n-butyl phthalate; MnBP: mono-n-butyl phthalate; DiBP: di-isobutyl phthalate; MiBP: monoisobutyl phthalate; BBzP: butyl benzyl phthalate; MBzP: monoben-
zyl  phthalate; DEHP: di(2- ethylhexyl) phthalate; 5-OH-MEHP: mono(2-ethyl-5-hydroxyhexyl) phthalate; 5-oxo-MEHP: mono(2-ethyl-5-oxohexyl) phthalate; 5-cx-MEPP:
mono(2-ethyl-5-carboxypentyl) phthalate; DiNP: diisononyl phthalate; MiNP: monoisononyl phthalate; OH-MiNP: monohydroxyisononyl phthalate; oxo-MiNP: monoox-
oisononyl phthalate; cx-MiNP: monocarboxylisononyl phthalate.
a Uncertainty of analysis must be taken into account.
b Münster, Germany.
Table 13
Reference values (RV95) for perfuorinated compounds in human plasma (according to Schulz et al., 2011).
Parameter Population group (age range) Years of the study RV95a
PFOA Women, men  and children < 10 yearsb 2003–2007 10 g/l
PFOS  Womenb 2003–2007 20 g/l
Menb 2003–2007 25 g/l
Children < 10 yearsb 2003–2007 10 g/l
ooctan
t
l
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aa Uncertainty of analysis must be taken into account.
b Not a strictly representative sample; PFOA: perﬂuorooctanoate; PFOS: perﬂuor
rations in whole blood, plasma and related to the blood lipid
evel. The new reference values reﬂect the trend of reduced PCB
xposure seen in different datasets. The RV95 values for children
ged 7–14 were determined on the basis of data collected in the
erman Environmental Survey for Children from 2003 to 2006.
he HBM Commission considers these to be sufﬁciently up to
ate.
Reference values given in Tables 4–13 have been established
arlier. They are presented to give a complete overview about allPlease cite this article in press as: Apel, P., et al., New HBM valu
values in force, and working principles of the German Human Bi
http://dx.doi.org/10.1016/j.ijheh.2016.09.007
vailable reference values.esulfonate.
6. Future prospects
For the perﬂuorinated compounds and other substances a revi-
sion of the reference values is necessary. Further data on the
exposure of children to diverse chemical substances are currently
collected in the context of the German Environmental Survey
2014–2017, GerES V. They will serve as a basis for an actualisation
of the reference values for the age group of 3–17 years in the ﬁrst
instance. Concerning the derivation of new HBM values one focuses for emerging substances, inventory of reference and HBM
omonitoring Commission. Int. J. Hyg. Environ. Health (2016),
of the Commission’s future work will be on the non phthalate plas-
ticisers and other health relevant substances with a high potential
for an increased exposure of the general population and/or with
a particular toxicological proﬁle. Additionally the cumulative risk
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